J1611 HCPCS code: Injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg
J1611 is the HCPCS Level II code for injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg. In 2024 Medicare paid an average of $95.74 per service for J1611 across 6,115 services. Its Medicare coverage code is D (Special coverage instructions apply): May be covered when national or local coverage criteria are met. The NCCI unit limit is 2 per day on outpatient hospital claims. Medicare volume rose 247% from 2023 to 2024 (1,764 to 6,115 services). In 2024, about 185 clinicians billed Medicare for J1611 for 5,217 beneficiaries; Florida, Minnesota, Arizona accounted for 85% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-01-01 |
| Last action effective | 2023-01-01 |
Who bills J1611 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 185 |
| Medicare beneficiaries | 5,217 |
| States with claims | 9 |
| Share of services in top 3 states (Florida, Minnesota, Arizona) | 85% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1611, 2023–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2023 | 1,764 | 1,668 | $117.38 | $93.26 |
| 2024 | 6,115 | 5,217 | $120.24 | $95.74 |
States with the most J1611 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 2,647 | $96.05 |
| Minnesota | 1,900 | $95.86 |
| Arizona | 615 | $95.28 |
| Texas | 474 | $95.21 |
| Alabama | 241 | $95.68 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 2 | Prescribing Information |
| practitioner claims | 2 | Prescribing Information |
What changed for J1611
- 2023-01-01: J1611 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1611?
J1611 is the HCPCS Level II code for injection, glucagon hydrochloride (fresenius kabi), not therapeutically equivalent to j1610, per 1 mg. Short descriptor: "Inj glucagon hcl, fresenius".
How much does Medicare pay for J1611?
In 2024, the average Medicare payment was $95.74 per service (average allowed $120.24).
Does Medicare cover J1611?
Coverage code D — Special coverage instructions apply. May be covered when national or local coverage criteria are met.
How many units of J1611 can be billed per day?
2 on outpatient hospital claims; 2 on practitioner claims (NCCI medically unlikely edits).
Related J16 codes
- J1600 — Injection, gold sodium thiomalate, up to 50 mg
- J1602 — Injection, golimumab, 1 mg, for intravenous use
- J1610 — Injection, glucagon hydrochloride, per 1 mg
- J1612 — Injection, glucagon (gvoke), 0.01 mg
- J1620 — Injection, gonadorelin hydrochloride, per 100 mcg
- J1626 — Injection, granisetron hydrochloride, 100 mcg
- J1627 — Injection, granisetron, extended-release, 0.1 mg
- J1628 — Injection, guselkumab, 1 mg
- J1630 — Injection, haloperidol, up to 5 mg
- J1631 — Injection, haloperidol decanoate, per 50 mg
- J1632 — Injection, brexanolone, 1 mg
- J1640 — Injection, hemin, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1611
- Watch J1611 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1611
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.